Scutellaria.

Baicalein and its glycoside baicalin are the main flavones that carry Scutellaria baicalensis activity. Adding isolated baicalein raises the same molecular load the whole extract delivers.

Chinese skullcap is the standardised preparation of the same root, so the two contribute to one shared flavone load rather than acting separately. Doses should be counted together.

Baicalin and berberine form a poorly soluble ion pair in solution, so how much of each dissolves changes when they are taken in the same preparation. The two roots have also been combined in classical bitter-cold formulas for centuries.

Licorice saponins act as natural surfactants that raise the solubility of poorly soluble flavones such as baicalin. The pairing is also standard in traditional scutellaria preparations.

Baicalin and baicalein carry catechol-type hydroxyls that bind ferric iron, forming complexes the gut absorbs poorly. Taking the two in the same dose lowers iron uptake, so separate them by a couple of hours.

Both are flavonoids cleared mainly by UGT glucuronidation and sulfation in the gut wall and liver. Given together they compete for the same conjugating capacity, which raises the circulating free fraction of each.

Baicalin, the dominant constituent of Scutellaria baicalensis root, is a glucuronide and is poorly absorbed intact. Gut bacterial beta-glucuronidase hydrolyses it to baicalein, which is the form that crosses the intestinal wall, and the aglycone is then re-glucuronidated in the enterocyte and liver. Systemic exposure therefore depends on the microbiota, which is why the same dose behaves differently between people and after antibiotic exposure.

A botanical mixture combining Boswellia serrata, Commiphora myrrha, propolis and Scutellaria baicalensis was evaluated as a single preparation in animals, with reduced expression of inflammatory signalling reported. Boswellic acids act on 5-lipoxygenase while Scutellaria flavones act on multiple arachidonic acid enzymes, so the two overlap on eicosanoid handling. This was measured in animals and as a fixed combination, so no individual contribution can be separated out.

Propolis appears alongside Scutellaria baicalensis in the same four-botanical veterinary mixture, and both contribute flavonoids that act on the same inflammatory transcription pathways. Propolis flavonoids include chrysin and galangin, structurally close to the Scutellaria flavones. The evidence is non-human and from a fixed blend rather than a factorial design.

Baicalin is the 7-O-glucuronide of baicalein and is the form the plant stores and the form most extracts are standardised on. It becomes the aglycone only after intestinal hydrolysis. Listing them together is a statement about what is actually absorbed rather than a combination proposal.

Wogonin and its glucuronide wogonoside are the second flavone pair in Scutellaria baicalensis root and are always present alongside baicalin in a whole-root extract. Wogonin carries a methoxy group at position 8 that changes its lipophilicity and its metabolic handling relative to baicalein. Any extract effect reflects the whole flavone set, not baicalin alone.

Luteolin and baicalein are both flavones and both are heavily glucuronidated and sulfated in the intestinal wall by the same UGT1A and SULT1A isoforms. Co-dosing loads shared conjugation capacity, which can raise the unconjugated fraction of either. The direction depends on relative dose and has not been quantified for this pair in people.

Apigenin competes with baicalein for the same intestinal glucuronidation and sulfation routes and for the efflux transporters that pump the conjugates back into the lumen. That competition is the usual explanation for non-linear flavonoid pharmacokinetics. It is a formulation consideration, not an added benefit.

Piperine inhibits intestinal UGT activity, and glucuronidation is the dominant first-pass barrier for baicalein. Reduced conjugation would raise systemic exposure to the aglycone. Piperine does the same for co-administered medicines, so the interaction is not selective and should be raised with a prescriber.

Rutin is a flavonol rhamnoglucoside that also requires bacterial hydrolysis before absorption, the same dependency baicalin has. Both rely on the glycosidase capacity of the colonic microbiota. Where that capacity is low neither is well absorbed, which is a shared limitation rather than a synergy.

Baicalein carries a catechol-like arrangement of adjacent hydroxyl groups on the A ring that binds divalent metal cations, and metal-baicalein complexes are well characterised in chemistry. In the gut lumen that binding can reduce free mineral available for uptake. Separating a Scutellaria dose from a mineral dose by a couple of hours is the practical response.

Copper is bound particularly strongly by flavonoid catechol and hydroxyl-ketone motifs, and baicalein-copper complexes are described in the coordination chemistry literature. The same chelation that reduces free copper also changes the redox behaviour of the flavonoid. Regard it as a mineral timing consideration.

Divalent calcium can form poorly soluble complexes with flavonoid glucuronides in the intestinal lumen, and baicalin calcium salts exist as a described material. The practical effect on absorption of either has not been measured in people. It belongs in a formulation note rather than a benefit claim.

Ascorbate regenerates flavonoid phenoxyl radicals back to the parent phenol after they have quenched an oxidant, a recycling relationship shown across the polyphenol class. That keeps a given amount of flavone functioning through more radical encounters. The chemistry is established; how much it matters at supplement doses in people is not.

Baicalein and wogonin bind the benzodiazepine site of the GABA-A receptor as positive modulators in binding and electrophysiology work, which is the accepted explanation for the calming reputation of both Scutellaria species. Supplemental GABA acts at the same receptor family but crosses into the brain poorly. Combining a modulator with an agonist of the same receptor is worth flagging for additive sedative effect.

L-theanine influences glutamate and GABA signalling and is commonly formulated for a calm-alert profile. Scutellaria flavones modulate the GABA-A benzodiazepine site directly. Stacking the two can produce more sedation than either alone, which matters before driving or operating machinery.

Valerian constituents act on GABA-A and adenosine signalling and are a standard evening botanical. Scutellaria flavones are positive allosteric modulators at the same receptor complex. The additive sedative effect is the reason the pair appears together in sleep formulas and also the reason to flag it.

Passiflora flavonoids, including chrysin-type compounds, act at the same benzodiazepine-sensitive site as the Scutellaria flavones. Formulas routinely combine them for that reason. Additive central depressant effect with alcohol or sedative medication is the practical caution.

Apigenin from chamomile binds the benzodiazepine site of GABA-A, structurally close to how the Scutellaria flavones act there. The two botanicals therefore converge on one receptor rather than complementing each other. Additive sedation is the expected result.

Melissa constituents including rosmarinic acid inhibit GABA transaminase, which slows GABA breakdown, while Scutellaria flavones modulate the receptor. Different steps of the same signalling system. Combined evening use can compound drowsiness.

Honokiol and magnolol are described as GABA-A positive modulators at a site distinct from the benzodiazepine site. Pairing them with Scutellaria flavones puts two modulators on one receptor complex. Sedative effects can add and the combination has not been characterised in people.

Melatonin acts on MT1 and MT2 receptors to shift sleep timing, a mechanism separate from GABA-A modulation. Evening formulas combine it with calming botanicals for that reason. The overlap is in the observed drowsiness rather than in the receptor.

Withanolides act on GABAergic signalling and on the hypothalamic-pituitary-adrenal axis, and ashwagandha appears in the same evening formulas as skullcap. Additive sedation is the expected interaction and it has not been quantified for the pair. Flagging it matters more than claiming a combined benefit.

Silymarin flavonolignans inhibit UGT and several CYP isoforms and are themselves cleared by glucuronidation, the same route baicalein depends on. Co-dosing loads one conjugation system with two substrates. Both botanicals also appear together in liver-support formulas, so the overlap is common in practice and worth stating.

Catechins inhibit catechol-O-methyltransferase and compete for the sulfotransferases and efflux transporters that also handle Scutellaria flavones. Both also chelate iron in the gut lumen. The interaction is on disposition rather than on any shared target.

Ginkgolide B antagonises platelet-activating factor, and baicalein inhibits 12-lipoxygenase in platelets, which is a documented in vitro property of the flavone. Two ingredients acting on platelet function from different angles is the reason to flag the pairing for anyone on anticoagulant or antiplatelet medication. No clinical bleeding outcome is being asserted here.

EPA displaces arachidonic acid from platelet membrane phospholipids and shifts thromboxane production toward the less aggregatory series-3 form. Baicalein acts on the lipoxygenase arm of the same arachidonic acid cascade. The combination is worth flagging where medication already affects clotting.

Allicin-derived compounds inhibit platelet aggregation in laboratory and some human work. Adding a lipoxygenase-active flavone from the same formula compounds the theoretical effect. This is a caution row rather than a benefit row.

Nattokinase has fibrinolytic activity in laboratory assays and is formulated for circulatory support. Combining it with a flavone that affects platelet lipoxygenase places two ingredients on the same physiological system. Anyone taking medication that affects clotting should raise the combination with a clinician.

Curcumin and baicalein are both cleared mainly by intestinal glucuronidation and both inhibit UGT isoforms, so they compete on the same limited capacity. They also converge on NF-kB signalling from different upstream points. Read the pairing as mechanistically overlapping with an unresolved pharmacokinetic interaction.

Resveratrol undergoes extensive sulfation and glucuronidation in the enterocyte, the identical bottleneck baicalein faces. Co-dosing two heavily conjugated polyphenols can raise the free fraction of both in an unpredictable way. Nothing here has been measured for the pair in humans.

Several flavonoids, baicalein among them, bind riboflavin transporters and the riboflavin-binding proteins in laboratory work, which is a described property of the flavone class. Any effect on riboflavin status at supplement doses in people has not been shown. It is listed as a mechanistic flag, not a depletion claim.